APR 07, 2016 10:30 AM PDT

Airbrushing the Poster Child: How ACOG's 2016 cervical cancer screening practice bulletin may impact molecular testing

C.E. CREDITS: P.A.C.E. CE
Speakers
  • Senior Director, Scientific Affairs at Roche Molecular Diagnostics
    Biography
      Dr. Ed Baker trained received his medical training in the Loma Linda University system. After completing his specialty training in Obstetrics and Gynecology, he practiced in the San Francisco bay area as a community physician for nearly 10 years. In 2002 he became interested in drug development and took a position with Organon Pharmaceuticals which was one of the most active companies focused on Women's health and eventually became the head of the women's health franchise Medical Affairs team.
      Dr. Baker has been involved in the development and registration of dozens of products for women's health and often lectures and writes on a variety of topics related to women's health. He has taken leadership positions for companies focused on areas outside of women's health. Prior to his current position he was head of Medical Affairs at Actelion Pharmaceuticals, a company that focused its efforts on rare diseases. He was attracted to his current position at Roche Molecular diagnostics because it presents a great opportunity to help shift a longstanding paradigm in cervical cancer screening. Dr. Baker remains a board certified OB/GYN and holds an appointment as Associate Professor of Medicine in the OB/GYN department at UC Davis.

    Abstract:

    Cervical cancer screening has been the 20th century poster child for preventative screening.  This presentation is a gynecologist’s perspective on its continuing evolution –both as a great success and an opportunity for improvement.    Dr Baker will focus on the transition from experience based to data driven development of guidelines for physicians.  He will also reflect on the challenges for molecular laboratories.   Their anticipation of changes in screening practice and potential impact to their range of services including consultative role to OB/Gyn physicians.  
     
    Learning objectives:
    1) The attendee will understand how and why the approach to cervical cancer screening is evolving.
    2) The attendee will understand how these changes might impact the molecular lab and it's relationship with OB/GYNs.
     
     


    Show Resources
    You May Also Like
    SEP 05, 2019 04:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 04:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    MAY 16, 2019 04:00 PM CEST
    C.E. CREDITS
    MAY 16, 2019 04:00 PM CEST
    DATE: May 16, 2019TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST The emergence of NGS is revolutionizing the microbiological sciences and transforming medicine. Deep sequencing has...
    AUG 27, 2019 09:00 AM PDT
    C.E. CREDITS
    AUG 27, 2019 09:00 AM PDT
    DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
    OCT 02, 2019 11:00 AM PDT
    OCT 02, 2019 11:00 AM PDT
    DATE: October 2, 2019TIME: 11:00am PDT, 2:00pm EDT Ditch the Excel spreadsheets and manage your molecular workflows entirely in your LIMS Achieve configuration of molecular workf...
    JUN 19, 2019 10:00 AM PDT
    JUN 19, 2019 10:00 AM PDT
    DATE: June 19, 2019TIME: 10:00am PDT, 1:00pm EDT As we develop new methods to create more biologically relevant models for research in understanding disease etiology and in...
    AUG 15, 2019 09:00 AM PDT
    C.E. CREDITS
    AUG 15, 2019 09:00 AM PDT
    DATE: August 15, 2019TIME: 9:00am PDT, 12:00pm EDT Radiation therapy is a critical tool for the treatment of brain tumors, however, exposure to high doses of ionizing radiation...
    Loading Comments...
    Show Resources